ADC Manufacturing: Conjugation, DAR Control, and Purification

What Is an Antibody-Drug Conjugate?

An antibody-drug conjugate (ADC) is a biopharmaceutical that combines the target specificity of a monoclonal antibody with the cell-killing potency of a cytotoxic small molecule, connected by a chemical linker. ADCs deliver highly potent payloads selectively to tumor cells, reducing systemic toxicity compared to conventional chemotherapy.

Every ADC consists of three components: the antibody (typically IgG1), the linker (cleavable or non-cleavable), and the cytotoxic payload (usually a microtubule inhibitor or DNA-damaging agent). The drug-to-antibody ratio (DAR) defines how many payload molecules are attached to each antibody and is the single most critical quality attribute in ADC manufacturing. Most approved ADCs target an average DAR of 2 to 4.

ADC manufacturing is more complex than standard mAb production because it adds chemical conjugation, DAR control, and payload-specific handling (including high-potency containment) to the standard biologic workflow. As of mid-2026, 15 ADCs have received FDA approval, and more than 200 ADC candidates are in clinical development.

Conjugation Chemistry: Cysteine, Lysine, and Site-Specific Methods

ADC conjugation chemistry determines where and how the payload attaches to the antibody, directly controlling DAR distribution, heterogeneity, and pharmacokinetics. Three conjugation approaches dominate the field, each with distinct trade-offs between simplicity, homogeneity, and manufacturing complexity.

Lysine Conjugation

Lysine conjugation attaches payload molecules to the approximately 80 exposed lysine residues on an IgG1 via NHS ester or isothiocyanate chemistry. Because many lysines are surface-accessible, this approach produces highly heterogeneous products with DAR values distributed from 0 to 8+ across more than 40 potential attachment sites. Kadcyla (ado-trastuzumab emtansine) and Mylotarg (gemtuzumab ozogamicin) use lysine conjugation. The stochastic nature yields a broad DAR distribution with an average around 3.5, but the number of distinct molecular species exceeds 10 million in theory.

Cysteine Conjugation

Cysteine conjugation is the most widely used approach in the current ADC pipeline. IgG1 antibodies contain four interchain disulfide bonds (two LC-HC and two HC-HC). Partial reduction with TCEP or DTT generates free thiols that react with maleimide-functionalized linker-payloads. Because reduction and conjugation occur at only 8 defined sites, cysteine conjugation produces a simpler mixture of DAR 0, 2, 4, 6, and 8 species. Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Polivy (polatuzumab vedotin) all use this approach.

Site-Specific Conjugation

Site-specific conjugation produces the most homogeneous ADCs by restricting payload attachment to 2 or 4 engineered sites. Major strategies include:

• Engineered cysteines (ThioMab technology) introduce unpaired cysteine residues at defined positions, enabling DAR 2 products with greater than 90% homogeneity after selective reduction and reoxidation.
• Transglutaminase conjugation uses microbial transglutaminase (mTG) to catalyze an amide bond between a glutamine residue (engineered or deglycosylated N297) and an amine-functionalized linker-payload.
• Glycan-based conjugation modifies the N297 glycan on the Fc region using glycosyltransferases to introduce azide-containing sugars, followed by strain-promoted azide-alkyne cycloaddition (SPAAC) click chemistry.
• Unnatural amino acid incorporation (e.g., para-azidophenylalanine) enables bioorthogonal click conjugation at genetically encoded positions.

How to Control the Drug-to-Antibody Ratio (DAR)

The drug-to-antibody ratio is the primary driver of ADC efficacy and safety. DAR directly affects potency (more drug per antibody means higher cell-killing), pharmacokinetics (higher DAR increases hydrophobicity and accelerates clearance), and therapeutic index. Controlling DAR during manufacturing requires precise management of the reduction step for cysteine-conjugated ADCs.

TCEP Stoichiometry for DAR Control

For cysteine conjugation, DAR is controlled by the molar ratio of the reducing agent TCEP to the antibody. IgG1 contains four interchain disulfide bonds: two between light chain and heavy chain (LC-HC) and two between the heavy chains (HC-HC) in the hinge region. TCEP reduces these bonds in a defined order.

• 1.0 mol eq TCEP:mAb reduces the two LC-HC disulfides preferentially, generating 4 free thiols and yielding an average DAR of 2.0.
• 2.0 mol eq TCEP:mAb reduces both LC-HC bonds and begins reducing HC-HC bonds, yielding an average DAR of 4.0.
• 4.0 mol eq TCEP:mAb fully reduces all four interchain disulfides, generating 8 free thiols and an average DAR of 8.0.

TCEP is preferred over DTT because it does not form mixed disulfides with antibody thiols and has better solution stability. After reduction, excess TCEP is removed by buffer exchange (tangential flow filtration or desalting) before adding the maleimide-functionalized linker-payload at 1.1-1.2 mol equivalents per free thiol to drive the conjugation reaction to completion.

Linker and Payload Selection

The linker connects the cytotoxic payload to the antibody and must remain stable in circulation while efficiently releasing the drug inside the target cell. Linker chemistry directly impacts ADC efficacy, safety, and manufacturing complexity.

Cleavable Linkers

Cleavable linkers exploit intracellular conditions to trigger drug release. The three main classes are:

• Protease-cleavable (Val-Cit dipeptide) are cleaved by cathepsin B in the lysosome. Used in Adcetris, Padcev, and Polivy with MMAE payload. Stable in plasma (half-life >100 hours) with rapid intracellular cleavage (half-life 1-2 hours). Enables bystander killing of adjacent antigen-negative cells.
• Acid-labile (hydrazone) hydrolyze at lysosomal pH 4.5-5.5. Used in early ADCs (Mylotarg). Less stable in circulation than protease-cleavable linkers, with plasma half-life of 48-72 hours.
• Disulfide linkers are reduced by intracellular glutathione (1-10 mM vs 5-15 μM in plasma). Steric hindrance from methyl groups flanking the disulfide improves plasma stability.

Non-Cleavable Linkers

Non-cleavable linkers (e.g., SMCC thioether in Kadcyla) release payload only after complete lysosomal degradation of the antibody. The released metabolite retains a charged amino acid residue, which limits membrane permeability and eliminates bystander killing. Non-cleavable linkers offer superior plasma stability (half-life >168 hours) and lower systemic toxicity.

Payload Classes

ADC payloads must be potent enough to kill cancer cells at the low intracellular concentrations achieved by antibody-mediated delivery (typically IC50 in the picomolar to low nanomolar range). The two dominant payload families are:

ADC Manufacturing Workflow

ADC manufacturing follows a defined sequence from mAb drug substance through conjugation, purification, and formulation. Each step operates under GMP conditions, with the conjugation and downstream steps requiring high-potency active pharmaceutical ingredient (HPAPI) containment due to the cytotoxic payload.

Key manufacturing considerations at each step:

• Reduction (Step 2): TCEP in phosphate/EDTA buffer at pH 7.0-7.4, 25°C, 1-2 hours. EDTA chelates trace metals that would catalyze disulfide reshuffling. Temperature and time are tightly controlled because over-reduction shifts the DAR distribution toward DAR 6-8.
• Conjugation (Step 3): Maleimide-linker-payload dissolved in DMSO or DMA (organic co-solvent at 5-10% v/v). Mixed rapidly into the reduced mAb at 4-25°C. Lower temperature favors selectivity for reduced interchain cysteines over surface-exposed thiols.
• Quenching (Step 4): N-acetyl cysteine (NAC) or free cysteine caps unreacted maleimide groups, preventing nonspecific conjugation during downstream processing.
• UF/DF (Step 6): Removes DMSO, excess reagents, and reaction byproducts. Exchanges into the formulation buffer (typically histidine-sucrose at pH 5.5-6.5). 30 kDa MWCO membranes retain the ADC (~155 kDa) while passing small-molecule impurities.

HIC Purification for DAR Species Separation

Hydrophobic interaction chromatography (HIC) is the reference technique for preparative-scale separation of ADC DAR species. Each conjugated drug molecule increases the surface hydrophobicity of the ADC in proportion to DAR, creating a hydrophobicity ladder that HIC resolves under non-denaturing conditions.

In a typical HIC process for a cysteine-conjugated ADC:

1. Load the crude conjugation mixture onto a butyl or phenyl HIC resin in high-salt buffer (1.5-2.0 M ammonium sulfate or sodium sulfate).
2. Elute with a decreasing salt gradient. DAR 0 (unconjugated mAb) elutes first, followed by DAR 2, DAR 4, DAR 6, and DAR 8.
3. Collect the target DAR 4 fraction, pooling only the peak center to maximize purity (typically >85% DAR 4 after HIC).

Gradient slope is the most important parameter: shallower gradients improve resolution between DAR species but increase processing time and buffer consumption. A typical preparative HIC run uses a linear gradient from 1.5 M to 0 M ammonium sulfate over 20-30 column volumes on butyl-Sepharose or Tosoh Butyl-650M resin.

In-Process and Release Analytics

ADC characterization requires a broader analytical panel than standard mAb testing because both the biologic and small-molecule components must be assessed, along with the conjugation itself. The critical quality attributes unique to ADCs are average DAR, DAR distribution, free (unconjugated) drug, and conjugation site occupancy.

DAR Measurement Methods

• HIC-HPLC resolves individual DAR species for cysteine-conjugated ADCs. The gold standard for DAR distribution analysis, with resolution of DAR 0 through DAR 8. Run time 30-60 minutes. Not effective for lysine-conjugated ADCs due to the large number of positional isomers.
• RP-HPLC (reversed-phase) under denaturing conditions separates light chain and heavy chain subunits with 0, 1, 2, or 3 drugs attached. Average DAR is calculated from peak areas. Effective for both cysteine and site-specific ADCs.
• Intact mass spectrometry (native MS) resolves individual DAR species by molecular weight. Deconvoluted spectra show peaks at 150 kDa (DAR 0), 152.6 kDa (DAR 2), 155.3 kDa (DAR 4), etc., with mass accuracy of 1-5 Da.
• UV spectroscopy (A280/A320) provides a rapid average DAR measurement using the differential absorbance of drug and antibody. Less precise than chromatographic methods but suitable for in-process monitoring.

Release Testing Panel

A typical ADC batch release panel includes:

• Average DAR by HIC-HPLC or RP-HPLC (specification: target ±0.5)
• DAR distribution (specification: ≥50% target DAR species for cysteine; ≥85% for site-specific)
• Aggregates by SEC-HPLC (specification: ≤5%, typically ≤2%)
• Free drug by RP-HPLC or free drug assay (specification: ≤2%)
• Potency by cell-based cytotoxicity assay (specification: 50-200% relative potency)
• Endotoxin by LAL (specification: ≤5 EU/mg)
• Intact mass by LC-MS (confirmation of expected molecular weight)
• Peptide mapping for conjugation site identification (informational for lysine; confirmatory for site-specific)

Scale-Up Considerations

ADC manufacturing scale-up from bench (1-10 mg) to clinical (1-100 g) to commercial (1-10 kg) presents unique challenges beyond those encountered in standard mAb manufacturing. The primary constraints are high-potency containment, organic co-solvent handling, and DAR consistency at scale.

High-Potency Containment

Most ADC payloads have occupational exposure limits (OELs) below 1 μg/m³, requiring Safebridge Category 4 or equivalent containment. All operations from linker-payload handling through fill-finish must occur in containment isolators or restricted-access barrier systems (RABS). Equipment surfaces must be validated for decontamination of the specific payload, and waste streams require inactivation before discharge.

Conjugation Mixing

The most critical scale-up parameter is mixing during linker-payload addition. At bench scale, rapid pipette addition achieves near-instantaneous mixing. At manufacturing scale (100-1,000 L), poor mixing during addition of the hydrophobic linker-payload in DMSO can create local concentration gradients that shift DAR distribution and increase aggregation. Strategies include:

• Static mixers or in-line mixing during payload addition for consistent micromixing
• Slow, controlled addition via peristaltic pump (typically 10-30 min addition time)
• Maintaining DMSO concentration below 10% v/v to prevent protein precipitation
• Temperature control at 4-25°C to prevent maleimide hydrolysis

Continuous Manufacturing

Continuous-flow ADC conjugation using coiled flow inverter reactors (CFIRs) or microreactors is emerging as an alternative to batch conjugation. Continuous processing offers improved heat and mass transfer, tighter DAR control through precise residence time distribution, and reduced HPAPI exposure. Several clinical-stage ADC programs have adopted continuous conjugation, with reported improvements in DAR distribution narrowness of 10-20% compared to batch.

Frequently Asked Questions

Related Tools

• Chromatography Calculator — Column sizing, gradient optimization, and resin lifetime for HIC and other chromatography modes.
• Filtration Calculator — TFF membrane sizing and diafiltration volume calculations for ADC UF/DF buffer exchange.
• Buffer Calculator — Prepare phosphate buffers, ammonium sulfate solutions, and formulation buffers for ADC manufacturing.

References

1. Beck A. et al. (2017). Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews Drug Discovery, 16(5), 315-337. doi:10.1038/nrd.2016.268
2. Junutula J.R. et al. (2008). Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnology, 26(8), 925-932. doi:10.1038/nbt.1480
3. Hamblett K.J. et al. (2004). Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clinical Cancer Research, 10(20), 7063-7070. doi:10.1158/1078-0432.CCR-04-0789
4. Weggen J.T. et al. (2024). Kinetic modeling of the antibody disulfide bond reduction reaction with integrated prediction of the drug load profile for cysteine-conjugated ADCs. Biotechnology and Bioengineering. doi:10.1002/bit.28899
5. Walsh S.J. et al. (2021). Site-selective modification strategies in antibody-drug conjugates. Chemical Society Reviews, 50(2), 1305-1353. doi:10.1039/D0CS00310G